Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 28,794 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

NCT06563804
View directory record Official record
Conditions
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
Interventions
S227928, Venetoclax
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Results available

Safety of Reduced Infliximab Infusion Time

NCT05340764
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

NCT04967664
View directory record Official record
Conditions
Post Surgical Neuropathic Pain
Interventions
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • Vista, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

A Study of the Long-Term Outcomes of HIV-Positive Patients

NCT00000932
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
91
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

NCT05037032
View directory record Official record
Conditions
Altitude, Sleep Apnea, Central
Interventions
Naltrexone Pill, Placebo
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

NCT04297332
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Behavioral Intervention, Informational Intervention, Nicotine Replacement, Telephone-Based Intervention
Behavioral · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Enrolling by invitation Phase 4 Interventional

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993
View directory record Official record
Conditions
Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Placebo (matching), Beta-blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 4 Interventional

Young Houston Emergency Opioid Engagement System

NCT04811014
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence, Opioid Overdose, Opioid Use, Substance Use Disorders
Interventions
Buprenorphine, Naloxone Drug Combination, Individual Counseling, Peer Recovery Support Services, Support Group, Referral to Medication Management, Assertive Outreach
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
13 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Inflammatory Challenge and Fear

NCT06630884
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection)
Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

NCT00690833
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybrido for Female Sexual Dysfunction

NCT01432665
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, Sildenafil, Testosterone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Brooksville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting No phase listed Observational

BPH Global Registry

NCT05543200
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Not listed
Lead sponsor
Société Internationale d'Urologie
Other
Eligibility
18 Years and older · Male only
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Pilot Randomized Control Trial Comparing Oral Ketamine and Oral Oxycodone for Pain Control in Emergency Department Patients

NCT07670507
View directory record Official record
Conditions
Pain Management
Interventions
oral ketamine, oxycodone
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279, Placebo, Apremilast
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Results available

Dutasteride for the Reduction of Alcohol Use in Male Drinkers

NCT01262287
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

NCT01472887
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
SAR3419
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Augusta, Georgia • Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393
View directory record Official record
Conditions
HIV Infections
Interventions
ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

NCT03451084
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ASLAN003
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 22, 2026, 4:57 AM EDT